Overactive Bladder Clinical Trial
Official title:
Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
The purpose of this study is to assess the effects of caffeine reduction/elimination on urinary symptoms in women with overactive bladders and compare this therapeutic approach to anticholinergic therapy. We hope to show a reduction in symptoms with caffeine reduction and determine how effective caffeine reduction is compared to medication. If caffeine reduction is shown to be beneficial, women may be encouraged to use this strategy before resorting to medications.
Urinary symptoms such as frequency, urgency, nocturia, and incontinence occur in many women.
Overactive bladder (OAB) accounts for forty to seventy percent of urinary incontinence.
These symptoms can be mildly annoying to life altering. Many women wear pads or adult
diapers daily and avoid social situations for fear of embarrassment. It is felt that up to
sixteen percent of the adult population may suffer from these symptoms and many of these
women seek medical help.
Currently, the standard of care for OAB includes some combination of lifestyle modification
counseling, bladder retraining, or anticholinergic medications. It is anticipated that
stimulants such as caffeine irritate the bladder and exacerbate OAB symptoms. There have
been a few studies looking at the effect of caffeine but interventions have varied, and the
results have been mixed.
Perhaps the most common treatment for significant OAB symptoms is the prescription of
anticholinergic medications. We know that these are efficacious in many women but they can
be expensive and have significant side effects4. In fact, many women discontinue their
anticholinergics due to dry mouth, dry eyes, gastrointestinal, and genitourinary effects.
To date there have been no studies comparing caffeine reduction to anticholinergic
medications.
Research Questions
1. Does caffeine reduction decrease OAB symptoms?
2. Does the amount of caffeine consumed relate to symptom severity?
3. If symptoms do improve with caffeine reduction, are women compliant with this
treatment?
4. How does caffeine reduction compare to anticholinergic medication in treating OAB?
Study Goal:Compare caffeine reduction to anticholinergic medication as a treatment for
overactive bladder.
Study Design:Randomized prospective study. Eligible participants will be randomized to
either the anticholinergic arm or the caffeine reduction arm.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT01122563 -
A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
|
N/A |